QC
NVCR icon

Quent Capital’s NovoCure NVCR Stock Holding History

Quent Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55
Closed -$711 – 1605
2025
Q3 		$711 Buy
+55
New +$735 ﹤0.01% 1342
2025
Q2 		– Sell
-59
Closed -$1.05K – 928
2025
Q1 		$1.05K Sell
59
-17
-22% -$386 ﹤0.01% 1207
2024
Q4 		$2.27K Hold
76
– – ﹤0.01% 1156
2024
Q3 		$1.19K Hold
76
– – ﹤0.01% 1260
2024
Q2 		$1.3K Sell
76
-52
-41% -$914 ﹤0.01% 1250
2024
Q1 		$2K Sell
128
-37
-22% -$544 ﹤0.01% 1230
2023
Q4 		$2.46K Buy
165
+47
+40% +$629 ﹤0.01% 1179
2023
Q3 		$1.91K Buy
118
+113
+2,260% +$3.26K ﹤0.01% 1185
2023
Q2 		$208 Sell
5
-14
-74% -$869 ﹤0.01% 1289
2023
Q1 		$1.14K Buy
19
+5
+36% +$400 ﹤0.01% 1233
2022
Q4 		$1.03K Buy
14
+5
+56% +$376 ﹤0.01% 1227
2022
Q3 		$1K Hold
9
– – ﹤0.01% 1169
2022
Q2 		$1K Hold
9
– – ﹤0.01% 1120
2022
Q1 		$1K Buy
+9
New +$663 ﹤0.01% 1211

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Quent Capital's NVCR Position: Q4 2025 in Review

Quent Capital sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 55 shares — an estimated $711 sold.

Quent Capital first reported a position in NVCR in Q1 2022 and held it in 14 quarters. The position peaked at $2.46K in Q4 2023. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Quent Capital reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Quent Capital sold 55 NovoCure shares in Q4 2025, an estimated $711.
  • Quent Capital first reported a position in NovoCure in Q1 2022 and held it in 14 quarters.
  • Quent Capital's NovoCure position peaked at $2.46K in Q4 2023.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Quent Capital's 13F filing for Q4 2025, filed 29 Jan 2026.